On September 3, 2025, Immunovant, a Roivant Sciences company, shared encouraging six-month off-treatment data from a proof-of-concept study of batoclimab in uncontrolled Graves’ disease (GD). These results were presented in an abstract for the 2025 Annual Meeting of the American Thyroid Association. The data provides evidence of potential disease modification for this autoimmune condition.
The study included a 24-week treatment period followed by a 24-week off-treatment follow-up period, with 21 patients entering the remission assessment phase. The results demonstrated strong durability of response and treatment-free remission in previously uncontrolled GD patients. This suggests that FcRn blockade could be an effective mechanism for treating Graves' disease.
Immunovant's lead compound, IMVT-1402, is currently being evaluated in two potentially registrational global trials for Graves’ disease, with topline readouts expected in 2027. The positive batoclimab data supports the broader FcRn franchise and its potential to address significant unmet needs in autoimmune diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.